• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 18.60
  • VXN 23.66
  • VXO 18.16
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

ENDP (Endo International plc)
Last Trade 9.59 Dividend/Share 0 PE Ratio 3.3
Date 12:20:26 PM Dividend Yield 0.000 Return on Assets -9.89
Change -0.04 ExDividend Date 0 Return on Capital null
Bid 9.59 Latest EPS -9.12 Price/Sale 0.966
Ask 9.62 LatestEPS Date 2017-12-31 Price to Book 2.64
Volume 28836 EPS ttm 2.910 Institutional % 135.7
Avg Volume 3.72M Shares Outstanding 224.34M Insider % 2.2
Open 9.61 Float 219.42M Short Ratio null
Prev Close 9.63 Return On Equity -406.28 5 Year Change % -0.863
High 9.87 Consensus EPS 0.6 2 Year Change % -0.263
Low 9.58 No. of Estimate 7.000 1 Year Change % 0.202
52 Week High 18.5 EPS Surprise $ null YTD Change % 0.249
52 Week Low 5.27 EPS Surprise Percent 0 6 Month Change % -0.088
52 Week Change 16.981 EBITDA 0M 3 Month Change % -0.449
50 Day MA 11.5674 Revenue 0M 1 Month Change % -0.055
200 Day MA Gross Profit 0M 5 Day Change % 0.032
Market Cap 2160.44M Cash 0M 30 Day Change % -0.200
Beta 1.061055 Debt 0M Stock Exchange Nasdaq Global Select
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Endo Pharmaceuticals Holdings Inc., through its subsidiary, Endo Pharmaceuticals Inc., engages in the research, development, manufacture, marketing, and sale of branded and generic prescription pharmaceuticals in the United States. Its primary products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana and Opana ER, and Percocet for the relief of moderate to severe pain; Voltaren Gel for use in treating pain associated with osteoarthritis; Frova for the acute treatment of migraine headaches in adults; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas for the palliative treatment of advanced prostate cancer; Valstar, a sterile solution for intravesical instillation of valrubicin and BCG-refractory CIS of the bladder; Hydron Implant, a reservoir-based drug delivery system available for parenteral administration; Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; and Sanctura XR to treat OAB symptoms. The company also offers generic products, including Endocet and morphine sulfate. In addition, it provides various development stage products, which primarily comprise Aveed for the treatment of male hypogonadism; Fortesta for testosterone replacement therapy in male hypogonadism; Octreotide implant for the treatment of acromegaly; Urocidin for the treatment of non-muscle-invasive bladder cancer that is currently undergoing Phase III clinical testing; and Axomadol in Phase II development for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The company has a strategic alliance agreement with Penwest Pharmaceuticals Co. Endo Pharmaceuticals Holdings was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania.